Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0006632003
Thu, 10.11.2022
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, November 10, 2022
Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the third quarter and first nine months 2022 results on November 16, 2022 at 10:00 pm CET (9:00 pm GMT [ … ]
Thu, 10.11.2022
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, November 10, 2022
Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the third quarter and first nine months 2022 results on November 16, 2022 at 10:00 pm CET (9:00 pm GMT [ … ]
Thu, 03.11.2022
MorphoSys AG
BOSTON, Mass., USA, November 3, 2022
MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
Presentations – including four oral sessions – feature data supporting the potential benefit of first-line therapy for pelabresib in myelofibrosis and tafasitamab i [ … ]
Thu, 03.11.2022
MorphoSys AG
BOSTON, Mass., USA, November 3, 2022
MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
Presentations – including four oral sessions – feature data supporting the potential benefit of first-line therapy for pelabresib in myelofibrosis and tafasitamab i [ … ]
Thu, 27.10.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 27, 2022
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AAC [ … ]
Thu, 27.10.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 27, 2022
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AAC [ … ]
Thu, 27.10.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 27, 2022
GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III [ … ]
Thu, 27.10.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 27, 2022
GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III [ … ]
Fri, 21.10.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 21, 2022
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)
Anticipated full year 2022 Monjuvi U.S. net product sales of approximately US$ 90 million
Morpho [ … ]
Fri, 21.10.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 21, 2022
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)
Anticipated full year 2022 Monjuvi U.S. net product sales of approximately US$ 90 million
Morpho [ … ]